Form 4: CFO Daniel Chevallard Buys LENZ Therapeutics Stock

LENZ Therapeutics' Chief Financial Officer, Daniel R. Chevallard, reported open market purchases of company common stock.

Summary

• Daniel R. Chevallard, Chief Financial Officer of LENZ Therapeutics, Inc., acquired 20 shares of common stock at a price of $22.71 per share.
• Additionally, Mr. Chevallard acquired 2,178 shares of common stock at a price of $22.7561 per share.
• These transactions occurred on November 7, 2025.
• Following these reported transactions, Mr. Chevallard directly beneficially owns a total of 5,386 shares of LENZ Therapeutics common stock.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the Chief Financial Officer's direct purchase of company stock, which signals strong insider confidence in the company's value and future performance.

Positives

• The Chief Financial Officer's purchase of company stock indicates confidence in the company's future prospects and valuation.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it reports a specific insider transaction.

Industry Context

Insider buying, particularly by a Chief Financial Officer, is often viewed by the market as a positive signal, suggesting that management believes the company's stock is undervalued or that significant positive developments are anticipated. This action aligns with a general trend where insider confidence can influence investor sentiment.

Stakeholder Impact

• Shareholders may interpret the CFO's stock purchase as a positive indicator of the company's health and future prospects, potentially increasing investor confidence.

Key Dates

Recommendation

The direct purchase of common stock by the Chief Financial Officer, Daniel R. Chevallard, is a strong signal of insider confidence. Such actions often precede positive company developments or reflect a belief that the stock is currently undervalued. While a single Form 4 filing does not constitute a complete investment thesis, it provides a compelling reason for investors to consider a 'buy' recommendation, especially when combined with other positive fundamentals.

Keywords

LENZ Therapeutics, LENZ, Insider Trading, Form 4, Stock Purchase, Daniel R. Chevallard, CFO, Common Stock